CancerDrs Find care

Cervical Cancer clinical trials in Illinois

37 actively recruiting cervical cancer trials at 63 sites across Illinois.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06568172
Sites in Illinois:
  • Alton Memorial Hospital — Alton, Illinois
  • Northwestern University — Chicago, Illinois
  • Rush MD Anderson Cancer Center — Chicago, Illinois
  • University of Illinois — Chicago, Illinois
  • Decatur Memorial Hospital — Decatur, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in Illinois:
  • Rush-Copley Medical Center — Aurora, Illinois
  • Advocate Outpatient Center - Aurora — Aurora, Illinois
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Illinois:
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • University of Chicago Comprehensive Cancer Center — Chicago, Illinois
  • Advocate Illinois Masonic Medical Center — Chicago, Illinois
  • AMG Crystal Lake - Oncology — Crystal Lake, Illinois
  • Cancer Care Specialists of Illinois - Decatur — Decatur, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in Illinois:
  • Site 50 — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Illinois:
  • University of Illinois Cancer Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
  • Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Illinois:
  • Saint Anthony's Health — Alton, Illinois
  • Rush - Copley Medical Center — Aurora, Illinois
  • Advocate Good Shepherd Hospital — Barrington, Illinois
  • OSF Saint Joseph Medical Center — Bloomington, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from wh…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05904080
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
  • University of Illinois — Chicago, Illinois
  • University of Chicago Comprehensive Cancer Center — Chicago, Illinois
  • Carle at The Riverfront — Danville, Illinois
  • Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Illinois:
  • Lurie Children's Hospital-Chicago — Chicago, Illinois
  • University of Chicago Comprehensive Cancer Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Illinois:
  • University of Chicago — Chicago, Illinois
  • Local Institution - 2142 — Peoria, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Illinois:
  • Orchard Healthcare Research Inc. — Skokie, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receiv…

Sponsor: EpicentRx, Inc.
NCT ID: NCT05966194
Sites in Illinois:
  • Northwestern University Feinberg School of Medicine — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

SMP-3124LP in Adults With Advanced Solid Tumors

An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT06526819
Sites in Illinois:
  • Northwestern Medicine Cancer Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of sh…

Sponsor: University of Chicago
NCT ID: NCT04683653
Sites in Illinois:
  • University of Illinois at Chicago (UIC) — Chicago, Illinois
  • University of Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or …

Sponsor: Northwestern University
NCT ID: NCT06959641
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squam…

Sponsor: University of Chicago
NCT ID: NCT07065630
Sites in Illinois:
  • The University of Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

This is a single-center phase 2 study of to test how well the combination of toripalimab with chemotherapy followed by TORS or risk and response stratified de-escalated (chemo)radiotherapy works in patients with in HPV16+ locoregionally ad…

Sponsor: University of Chicago
NCT ID: NCT07290621
Sites in Illinois:
  • The University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Illinois:
  • Ingalls Family Care Center — Calumet City, Illinois
  • UChicago Medicine - River East — Chicago, Illinois
  • The University Of Chicago — Chicago, Illinois
  • University of Chicago Medical Center — Chicago, Illinois
  • UChicago Medicine at Ingalls - Flossmoor — Flossmoor, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Illinois:
  • Exelixis Clinical Site #26 — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Illinois:
  • Illinois Cancer Specialists — Arlington Heights, Illinois
  • University of Illinois — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04704661
Sites in Illinois:
  • Memorial Hospital East — Shiloh, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JAN…

Sponsor: Janux Therapeutics
NCT ID: NCT05783622
Sites in Illinois:
  • University of Chicago Medical Center — Chicago, Illinois
View on ClinicalTrials.gov →

Showing 25 of 37 trials with sites in Illinois. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20